Interim Phase 2 ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL.
Oncology (Williston Park)
; 34(7): 260, 2020 Jul 15.
Article
em En
| MEDLINE
| ID: mdl-32674213
ABSTRACT
Results from an interim analysis of the phase 2 ZUMA-5 study showed that axicabtagene ciloleucel (axicel;Yescarta) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma, with high overall response rate (ORR) and complete response (CR) rate observed. It also had a manageable safety profile.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article